NovaBay Pharmaceuticals Company Profile (NYSE:NBY)

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals logoNovaBay Pharmaceuticals, Inc., formerly NovaCal Pharmaceuticals, Inc., is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox. Its Avenova with Neutrox removes debris from the skin on the eyelids and lashes without burning or stinging. It develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. Its Aganocide compounds, led by auriclosene (NVC-422), are synthetic molecules with activity against bacteria, viruses and fungi. The Company's dermatology product includes CelleRx, a cleansing solution for post laser resurfacing, chemical peels and other cosmetic surgery procedures. Its wound care business includes the business of NeutroPhase product.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: NBY
  • CUSIP:
Key Metrics:
  • Previous Close: $4.10
  • 50 Day Moving Average: $3.78
  • 200 Day Moving Average: $3.75
  • 52-Week Range: $1.77 - $5.29
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -16.40
  • P/E Growth: 0.00
  • Market Cap: $62.05M
  • Outstanding Shares: 15,134,000
Additional Links:

Analyst Ratings

Consensus Ratings for NovaBay Pharmaceuticals (NYSE:NBY) (?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $6.00 (46.34% upside)

Analysts' Ratings History for NovaBay Pharmaceuticals (NYSE:NBY)
DateFirmActionRatingPrice TargetDetails
2/6/2017Rodman & RenshawInitiated CoverageBuy$6.00View Rating Details
1/19/2017Maxim GroupReiterated RatingHoldView Rating Details
(Data available from 2/21/2015 forward)


Earnings History for NovaBay Pharmaceuticals (NYSE:NBY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/10/2016Q316($0.16)($0.34)$3.02 million$3.40 millionViewN/AView Earnings Details
8/11/2016Q216($0.30)($0.36)$1.76 million$2.70 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for NovaBay Pharmaceuticals (NYSE:NBY)
Current Year EPS Consensus Estimate: $-1.69 EPS
Next Year EPS Consensus Estimate: $-0.25 EPS


Dividend History for NovaBay Pharmaceuticals (NYSE:NBY)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for NovaBay Pharmaceuticals (NYSE:NBY)
No insider trades for this company have been tracked by


Latest Headlines for NovaBay Pharmaceuticals (NYSE:NBY)
DateHeadline logoNovaBay sees 171% jump in 2016 revenues; shares ahead 8% (NYSE:NBY) - January 9 at 7:28 PM
News IconNovaBay Pharmaceuticals, Inc. NBY Medical Equipment Deals and Alliances Profile Prices from USD $250 (NYSE:NBY) - January 8 at 3:53 AM logoNovabay Pharma : Niobay Metals announces Flow-Through Financing of up to $1,000,000 (NYSE:NBY) - December 12 at 10:08 AM logoNovaBay Pharma (NBY) Notes Positive OCLI Publication on Avenova (NYSE:NBY) - November 29 at 2:40 PM logoNovaBay Pharma (NBY) Misses Q3 EPS by 18c (NYSE:NBY) - November 11 at 6:05 PM logoNovaBay Pharmaceuticals' (NBY) CEO Mark Sieczkarek on Q3 2016 Results - Earnings Call Transcript (NYSE:NBY) - November 11 at 6:05 PM logoNovaBay Pharmaceuticals Reports 2016 Third Quarter Financial Results (NYSE:NBY) - November 10 at 6:07 PM logoNovaBay regains compliance with NYSE continued listing requirements (NYSE:NBY) - October 31 at 1:07 PM logoNovaBay Pharmaceuticals Complies With NYSE Listing Requirements (NYSE:NBY) - October 31 at 1:07 PM logoNovaBay pulls in $7M from exercise of warrants (NYSE:NBY) - October 3 at 10:55 AM logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of NovaBay Pharmaceuticals, Inc. - NBY (NYSE:NBY) - September 23 at 3:30 PM logo15 Stocks Moving In Monday's Pre-Market Session (NYSE:NBY) - September 19 at 8:39 AM logoBest Stocks: Denbury Resources Inc. (NYSE:DNR), NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY), Linn Energy ... - KC Register (NYSE:NBY) - May 23 at 3:06 PM logoNovaBay misses by $0.56, misses on revenue - Seeking Alpha (NYSE:NBY) - May 13 at 7:21 AM logoNovaBay Pharmaceuticals Reports 2016 First Quarter Financial Results (NYSE:NBY) - May 12 at 5:27 PM
News IconNovaBay Pharmaceuticals, Inc. (NBY) to Release Earnings on Thursday - Washington News Wire (NYSE:NBY) - May 12 at 7:31 AM logoNovaBay Pharmaceuticals to Hold First Quarter 2016 Conference Call on May 12 (NYSE:NBY) - May 5 at 7:00 AM logoNovaBay Says Its Avenova Cuts Bacteria On Ocular Skin Surface By Over 90% - Benzinga (NYSE:NBY) - May 4 at 6:17 AM logoWorth Watching Stocks: Epizyme, Inc. (NASDAQ:EPZM), NovaBay Pharmaceuticals (NYSEMKT:NBY), Express Scripts ... - KC Register (NYSE:NBY) - May 2 at 6:58 AM logoStock Highlights: NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY), Xplore Technologies Corp. (NASDAQ:XPLR ... - KC Register (NYSE:NBY) - April 29 at 7:31 AM
News IconNovaBay Pharmaceuticals, Inc. (NYSE:NBY) Given Average Recommendation of “Hold” by Brokerages - Washington News Wire (NYSE:NBY) - April 13 at 1:06 PM logoNovaBay Pharma (NBY) Enters $12M Securities Purchase Agreement - (NYSE:NBY) - April 6 at 12:56 PM
News IconOrbitronix Lp buys $39391 stake in NovaBay Pharmaceuticals (NBY) - SCSUCollegian (NYSE:NBY) - April 3 at 12:44 PM
News IconNovabay Pharmaceuticals Incorporated (NYSEMKT:NBY) Shorted Shares Increased 119.85% After Market Selling - (NYSE:NBY) - March 31 at 1:25 PM logoNovabay Pharmaceuticals Incorporated (NYSEMKT:NBY) Sellers Increased By 6.7% Their Shorts - Clinton Financial (NYSE:NBY) - March 20 at 12:58 PM
News IconNovabay Pharmaceuticals Incorporated (NYSEMKT:NBY) Shorted Shares Increased 6.7% After Market Selling - Business Standard Tribune (NYSE:NBY) - March 17 at 11:59 AM logoNovaBay Pharmaceuticals to Present at 28th Annual ROTH Conference - Business Wire (press release) (NYSE:NBY) - March 8 at 1:08 PM
News IconPioneer Pharma (Singapore) Pte. Ltd Sold More Novabay Pharmaceuticals, Inc Shares - (NYSE:NBY) - March 5 at 12:59 PM
News IconQ4 Results: NovaBay Pharmaceuticals Inc. (NBY) - share market updates (press release) (NYSE:NBY) - March 5 at 12:59 PM
News IconNovaBay Pharmaceuticals, Inc.'s Stock Is Sell After Today's Huge Decline - (NYSE:NBY) - March 1 at 8:11 PM
News IconNovabay Pharmaceuticals Incorporated (NYSEMKT:NBY) Shorted Shares Decreased By 23.25% - (NYSE:NBY) - February 29 at 7:59 PM logoWhat Will Happen to NovaBay Pharmaceuticals, Inc. Next? The Stock Just Increased A Lot - Clinton Financial (NYSE:NBY) - February 28 at 12:27 PM logoNovaBay Pharma (NBY) Announces $2.83M Private Placement - (NYSE:NBY) - February 24 at 7:47 PM logo4:50 pm NovaBay Pharma confirms $2.83 mln private placement (NYSE:NBY) - February 24 at 4:50 PM logoNovaBay Pharmaceuticals Announces $2.83 Million Private Placement (NYSE:NBY) - February 24 at 4:48 PM
News IconThe Lists Top 10 Wall Street Losers of ... - Genetic Engineering & Biotechnology News (NYSE:NBY) - February 22 at 7:23 PM
News IconNovabay Pharmaceuticals Incorporated (NYSEMKT:NBY) Short Interest Decreased By 4.14% - Stock Caller (NYSE:NBY) - February 22 at 7:23 PM
News IconNovabay Pharmaceuticals Incorporated (NYSEMKT:NBY) Shorts Decreased by 4.14% After Short Covering - (NYSE:NBY) - February 16 at 11:57 AM logoNew Market Research Report: NovaBay Pharmaceuticals, Inc. (NBY) - Medical Equipment - Deals and Alliances Profile (NYSE:NBY) - February 3 at 10:48 AM logoHot Alert: NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY), Arlington Asset Investment Corp. (NYSE:AI), Potlatch ... - KC Register (NYSE:NBY) - January 20 at 5:21 PM


What is NovaBay Pharmaceuticals' stock symbol?

NovaBay Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "NBY."

Where is NovaBay Pharmaceuticals' stock going? Where will NovaBay Pharmaceuticals' stock price be in 2017?

2 brokerages have issued 1-year price objectives for NovaBay Pharmaceuticals' stock. Their predictions range from $6.00 to $6.00. On average, they anticipate NovaBay Pharmaceuticals' stock price to reach $6.00 in the next twelve months.

When will NovaBay Pharmaceuticals announce their earnings?

NovaBay Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March, 1st 2017.

How do I buy NovaBay Pharmaceuticals stock?

Shares of NovaBay Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of NovaBay Pharmaceuticals stock cost?

One share of NovaBay Pharmaceuticals stock can currently be purchased for approximately $4.10.

NovaBay Pharmaceuticals (NYSE:NBY) Chart for Tuesday, February, 21, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for NovaBay Pharmaceuticals (NYSE:NBY)

Earnings History Chart

Earnings by Quarter for NovaBay Pharmaceuticals (NYSE:NBY)

Dividend History Chart

Dividend Payments by Quarter for NovaBay Pharmaceuticals (NYSE:NBY)

Last Updated on 2/21/2017 by Staff